Bio-Path HoldingsBPTH +21.43% Current Ratio is 0.07 as of Mar. 2026, which is 99% below its 10-year median of 9.27. The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, Bio-Path Holdings ranks worse than 98.09% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Bio-Path Holdings's current ratio for the quarter that ended in Mar. 2026 was 0.07.
Bio-Path Holdings has a current ratio of 0.07. It indicates that the company may have difficulty meeting its current obligations. Low values, however, do not indicate a critical problem. If Bio-Path Holdings has good long-term prospects, it may be able to borrow against those prospects to meet current obligations.
The historical rank and industry rank for Bio-Path Holdings's Current Ratio or its related term are showing as below:
BPTH'
s Current Ratio Range Over the Past 10 Years
Min: 0.07 Med: 9.27 Max: 27.29
Current: 0.07
During the past 13 years, Bio-Path Holdings's highest Current Ratio was 27.29. The lowest was 0.07. And the median was 9.27.
BPTH's Current Ratio is ranked worse than 98.09% of 1417
companies
in the Biotechnology industry
Industry Median: 3.89
vs BPTH: 0.07
Bio-Path Holdings (OTCPK:BPTH) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Bio-Path Holdings Current Ratio Related Terms
Bio-Path Holdings Current Ratio Historical Data
* Premium members only.
The historical data trend for Bio-Path Holdings's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BPTH vs ADAPY, ZVSA, CLSDQ: Current Ratio Comparison
For the Biotechnology subindustry, Bio-Path Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio-Path Holdings Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bio-Path Holdings's Current Ratio distribution charts can be found below:
* The bar in red indicates where Bio-Path Holdings's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Path Holdings (BPTH) has a Current Ratio of 0.07 as of Mar. 2026. This is 99% below median its historical median of 9.27. Over the past decade, Bio-Path Holdings' Current Ratio has ranged from 0.07 to 27.29. According to the industry distribution chart, Bio-Path Holdings ranks #1390 out of 1417 companies in the Biotechnology industry, placing it in the top 98.1%.
Is Bio-Path Holdings' Current Ratio too high?
Bio-Path Holdings' current Current Ratio of 0.07 is 99% below median its 10-year median of 9.27. Over the past 10 years, this metric has ranged from a low of 0.07 to a high of 27.29. The Biotechnology industry median Current Ratio is 3.89. Bio-Path Holdings' value of 0.07 is 98.2% below this industry median. Based on the distribution chart, Bio-Path Holdings ranks #1390 out of 1417 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Bio-Path Holdings' Current Ratio compare to ADAPY and ZVSA?
According to the Biotechnology industry distribution chart, Bio-Path Holdings ranks #1390 out of 1417 companies for Current Ratio. This places Bio-Path Holdings in the lower half of its industry. The industry median Current Ratio is 3.89. Bio-Path Holdings' value of 0.07 is 98.2% below this benchmark. Historically, Bio-Path Holdings' own Current Ratio has ranged from 0.07 to 27.29 over the past decade. While the company's 10-year median is 9.27 vs. the industry median of 3.89, Bio-Path Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.89, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio-Path Holdings's current Current Ratio of 0.07 is 98.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.89 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio-Path Holdings's current Current Ratio is 0.07, which is 99% below median its own 10-year median of 9.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Path Holdings stock overvalued right now?
Bio-Path Holdings (BPTH) has a current Current Ratio of 0.07. The current Current Ratio is 0.07, which is 99% below median its 10-year median of 9.27 and 98.2% below the Biotechnology industry median of 3.89. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Bio-Path Holdings (BPTH), the current Current Ratio is 0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's drug candidate, prexigebersen, is in the efficacy portion of a Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. The other drugs of the company are BP1002, BP1003, BP1001-A, and DNABILIZE.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BPTH has been successfully added to your 